Most of the presentations at SABCS focus on the latest clinical and basic research results relating to breast cancer. By contrast, educational sessions are designed to inform and update those interested in a review on a particular topic. Although these sessions may include new specific research findings, their primary intent is to offer summaries of existing knowledge, and to provide background for some of the active areas which will be discussed in the rest of the meeting.
Multidisciplinary Approach to Optimizing Local Regional Therapy in Hormone Receptor Positive Breast Cancer
Moderator: Armando Giuliano, MD
Cedars-Sinai Medical Center
Los Angeles, CA
Decision making regarding timing of therapy: upfront surgery? Neoadjuvant chemotherapy? Neoadjuvant endocrine therapy?
Otto Metzger, MD
Dana-Farber Cancer Institute,
Boston, MA
Surgical management of the upfront surgery patient
Melissa L. Pilewskie, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Local regional therapy considerations after preoperative therapy in hormone receptor positive breast cancer
Tari Ann King, MD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA
Tailoring Adjuvant Therapies Based on Neoadjuvant Response
Moderator: Charles E. Geyer, MD
Virginia Commonwealth University
Massey Cancer Center
Richmond, VA
The biology and plasticity of residual disease
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC
Clinical management
Jenny C. Chang, MD
Houston Methodist Hospital
Houston, TX
Locoregional
Julia White, MD
The Ohio State University
Columbus, OH
Targeted Treatment Beyond PARP1 Inhibition
Moderator: Alexander Bishop, DPhil
Greehey Children's Cancer Research Institute
UT Health San Antonio
San Antonio, TX
Clinical indications of PARP1 inhibitors and other targets
Melinda L. Telli, MD
Stanford University Medical Center
Stanford, CA
Novel DNA repair targets for breast cancer
Thomas Helleday, PhD
University of Sheffield
Sheffield, UNITED KINGDOM
Clinically relevant biomarkers of PARP1 inhibitor resistance and indicators of targeted combinatorial treatments
Violeta Serra, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN
Implementation of Genetic Testing in Breast Cancer Patients
Moderator: Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX
Genetic testing for hereditary breast cancer: Who should be tested?
Nadine Tung, MD
Beth Israel Deaconess Medical Center
Boston, MA
Approaches to genetic counseling and testing
Banu Arun, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Impact of genetic information for breast cancer patients
Judith Balmaña, MD, PhD
Vall d'Hebron Institute of Oncology
Barcelona, SPAIN
Acquired Endocrine Therapy Resistance Beyond ESR1 Mutations
Moderator: Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
Adaptive resistance
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
Exploiting single cell transcriptome analyses to track adaptation to endocrine therapies
Luca Magnani, PhD
Imperial College London
London, UNITED KINGDOM
The genomic landscape of endocrine-resistant metastatic breast cancer
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
Breast Cancer Prevention
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA
Targeted approach to breast cancer surveillance in high risk women: Update of the newest technologies and how to use them
Maxine S. Jochelson, MD
Memorial Sloan Kettering Cancer Center
New York, NY
Risk-based recommendations: considering the time-frame
Seema A. Khan, MD
Northwestern University
Chicago, IL
Low dose tamoxifen and other approaches to improve chemoprevention uptake
Andrea DeCensi, MD
E.O. Ospedali Galliera
Genova, ITALY
Evolving Opportunities to Personalize Radiation Decisions
Moderator: Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI
Guiding decisions to omit RT after BCS in DCIS
Eileen Rakovitch, MD, FRCP(C), MSc
Sunnybrook Health Sciences Centre
Toronto, CANADA
Guiding decisions to omit radiation after breast conserving surgery for invasive breast cancer
Corey Speers MD, PhD
University of Michigan
Ann Arbor, MI
Guiding selection of RT approach after lumpectomy
Simona Shaitelman, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Conversations on Tough Topics Surrounding Cancer Care
Moderator: Susan Rafte
Community Advocate, Baylor College of Medicine Breast Center
Houston, TX
Progression of disease and end of life: How to break bad news
Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA
The toll on health care providers
Sharon H. Giordano, MD, MPH, FASCO
University of Texas MD Anderson Cancer Center
Houston, TX
Financial toxicities
Rachel Greenup, MD, MPH
Duke University School of Medicine
Durham, NC
Panel Discussion
TNBC: Immunotherapy and Beyond
Moderator: Sylvia Adams, MD
NYU Langone Health
New York, NY
Immunotherapy in metastatic and neoadjuvant breast cancer
Rita Nanda, MD
University of Chicago
Chicago, IL
Detecting and managing IO related toxicities wisely
Peter Schmid, MD, PhD
Barts Cancer Institute
London, UNITED KINGDOM
Detect or not detect - the question is PD-L1/PD-1 how, when, why
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT
Breast Cell Fate Control and Plasticity
Moderator: Yi Li, PhD
Baylor College of Medicine
Houston, TX
Lineage tracing of mammary cells
Cedric Blanpain, MD, PhD
Universite Libre de Bruxelles
Bruxelles, BELGIUM
Cell state plasticity
Geoffrey Wahl, PhD
Salk Institute for Biological Studies
La Jolla, CA
Cell fate plasticity during breast cancer development -
where is the translational utility?
Christina Scheel, MD
Helmholtz Center Munich
Institute of Stem Cell Research
Neuherberg, GERMANY
Endocrine Therapy 2020
Moderator: Mothaffar Rimawi, MD
Baylor College of Medicine
Houston, TX
Adjuvant endocrine therapy in 2020: It's complicated
Angelo Di Leo, MD, PhD
Hospital of Prato
Prato, ITALY
Endocrine therapy beyond 2020 (metastatic, new agents)
Erica L. Mayer, MD, MPH
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
Everything comes with a price (toxicity)
Dawn Hershman, MD
Columbia University Medical Center
New York Presbyterian Hospital
New York, NY